FindTrial
Sign In

cyclodextrin-based polymer-camptothecin CRLX101

DRUG2 trials

Sponsors

City of Hope Medical Center, University of Chicago

Conditions

Adenocarcinoma of the EsophagusAdenocarcinoma of the Gastroesophageal JunctionDiffuse Adenocarcinoma of the StomachExtensive Stage Small Cell Lung CancerIntestinal Adenocarcinoma of the StomachMixed Adenocarcinoma of the StomachRecurrent Esophageal CancerRecurrent Gastric Cancer

Phase 2

Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
CompletedNCT01612546
City of Hope Medical CenterAdenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach +11
Start: 2012-11-30End: 2015-01-15Updated: 2018-02-01
Topotecan Hydrochloride or Cyclodextrin-Based Polymer-Camptothecin CRLX101 in Treating Patients With Recurrent Small Cell Lung Cancer
TerminatedNCT01803269
University of ChicagoExtensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
Start: 2013-01-16End: 2016-03-30Updated: 2020-06-26

Related Papers

Pilot trial of CRLX101 in patients (pts) with advanced, chemotherapy-refractory gastroesophageal cancer (GEC).
Journal of Clinical Oncology2016-02-011 citations
Abstract B33: CRLX101, an investigational nanoparticle-drug conjugate, localizes in human tumors and not in adjacent healthy tissue after intravenous dosing
Molecular Cancer Therapeutics2015-12-01